Diacerein - TWi Biotechnology

Drug Profile

Diacerein - TWi Biotechnology

Alternative Names: AC-201; AC-201 Controlled release tablet; AC-201CR; AC-203; CCP 020

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TWi Biotechnology; TWi Pharmaceuticals
  • Developer Castle Creek Pharmaceuticals; TWi Biotechnology
  • Class Anthraquinones; Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Small molecules
  • Mechanism of Action Caspase 1 inhibitors; Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Epidermolysis bullosa
  • Phase II Bullous pemphigoid; Gout; Joint disorders; Type 2 diabetes mellitus
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 05 Sep 2017 Phase-II clinical trials in Bullous pemphigoid in Taiwan (Topical) (NCT03286582)
  • 31 May 2017 Phase-II/III clinical trials in Epidermolysis bullosa (In children, In adolescents, In adults, In the elderly) in USA (Topical) (9217821; NCT03154333)
  • 18 May 2017 Castle Creek Pharmaceuticals plans a phase II trial for Epidermolysis bullosa (NCT03154333)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top